Carisma Therapeutics, Inc.
CARM · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $3,729 | $3,653 |
| % Growth | – | -100% | 2.1% | – |
| Cost of Goods Sold | $0 | $356 | $0 | $669 |
| Gross Profit | $0 | -$356 | $3,729 | $2,984 |
| % Margin | – | – | 100% | 81.7% |
| R&D Expenses | $197 | $2,424 | $9,156 | $15,578 |
| G&A Expenses | $1,239 | $3,354 | $3,907 | $5,930 |
| SG&A Expenses | $1,239 | $3,354 | $3,907 | $7,878 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $1,948 |
| Other Operating Expenses | $0 | -$356 | $0 | -$2,617 |
| Operating Expenses | $1,436 | $5,422 | $13,063 | $20,839 |
| Operating Income | $43,814 | -$5,778 | -$9,334 | -$17,855 |
| % Margin | – | – | -250.3% | -488.8% |
| Other Income/Exp. Net | $903 | -$3,996 | $68 | $220 |
| Pre-Tax Income | $44,717 | -$9,774 | -$9,266 | -$17,635 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | $44,717 | -$9,774 | -$9,266 | -$17,635 |
| % Margin | – | – | -248.5% | -482.8% |
| EPS | 1.07 | -0.23 | -0.22 | -0.42 |
| % Growth | 565.2% | -4.5% | 47.6% | – |
| EPS Diluted | 1.07 | -0.23 | -0.22 | -0.42 |
| Weighted Avg Shares Out | 41,788 | 41,788 | 41,771 | 41,456 |
| Weighted Avg Shares Out Dil | 41,940 | 41,788 | 41,771 | 41,456 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $470 | $68 | $220 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $356 | $661 | $669 |
| EBITDA | $44,717 | -$5,422 | -$8,673 | -$16,966 |
| % Margin | – | – | -232.6% | -464.4% |